Take a trial of UK to unlock this pageFind out more


AZN 4000.5p -14.0  -0.3%
11:17am 0.500k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 2 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 TTM 2016E 2017E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 11th Aug, paid: 12th Sep more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ -2.4%

FINANCIAL BRIEF: For the three months ended 31 March 2016, AstraZeneca plc revenues increased 1% to $6.12B. Net income increased 17% to $646M. Revenues reflect United States segment increase of 4% to $2.25B. Net income benefited from Selling, General decrease of 10% to $2.13B (expense), Cost OF Sales - Restructuring Costs decrease of 79% to $9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from $0.44 to $0.51. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2016
31st Dec 2017

Price Target: $68.2
(+16.21% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: -1.7% ($) (¢) (¢) ($) (¢) (¢)
Consensus Estimate
1m Change
3m Change
30 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 2 14 11 6

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Matthew Weston , SEB Equities , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Danske Markets , Panmure Gordon , Natixis Jean-Jacques Le Fur , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Michael Novod , Societe Generale Justin Smith , Pareto Securities AS Finlay Heppenstall , Berenberg Alistair Campbell , Oddo Securities Pierre Corby , Helvea SA Odile Rundquist , Shore Capital Stockbrokers Tara Raveendran , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Cantor Fitzgerald Europe Brian White , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Directors: Pascal Soriot (CEO) 56, Marc Dunoyer (CFO) 62, Fiona Cicconi (EVP) , Sean Bohen (EVP) , Ruud Dobber (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Luke Miels (EVP) , Menelas Pangalos (EVP) , Leif Johansson (NEC) 65, Cornelia Bargmann (NED) , Genevieve Berger (NED) 60, Ann Cairns (NED) 59, Tim Jackson-Smith (NED) ,

No. of Employees: 61,500 No. of Shareholders: 97,260

Last Annual December 31st, 2015
Last Interim March 31st, 2016
Incorporated June 17, 1992
Public Since September 21, 2007
Shares in Issue 1,264,547,248
Free Float 1.26bn (99.8%)

Address - Legal Department 2 Kingdom Street, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 73045000
Contact Thomas Larsen (IR Contact Officer)
Auditors KPMG LLP

AZN Share Price Performance AZNQuote
-14.0  -0.3%
Traded 11:17am · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Wednesday 8th June, 2016
AstraZeneca PLC at Jefferies Healthcare Conference
Tuesday 21st June, 2016
AstraZeneca PLC at Citi European Healthcare Conference
Tuesday 5th July, 2016
AstraZeneca PLC IR Roadshow - Cologne, Stuttgart
Wednesday 6th July, 2016
AstraZeneca PLC IR Roadshow - Munich
Thursday 28th July, 2016
Q2 2016 AstraZeneca PLC Earnings Release
Thursday 10th November, 2016
Q3 2016 AstraZeneca PLC Earnings Release

Recent ↓
Friday 29th April, 2016
AstraZeneca PLC Annual Shareholders Meeting
Friday 29th April, 2016
Q1 2016 AstraZeneca PLC Earnings Call
Friday 29th April, 2016
Q1 2016 AstraZeneca PLC Earnings Release
Tuesday 26th April, 2016
Ironwood Pharmaceuticals Inc Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad Conference Call
Thursday 31st March, 2016
AstraZeneca PLC at Bank of America Merrill Lynch Investor Relations Insights Conference
Friday 18th March, 2016
AstraZeneca PLC at Carnegie Healthcare Seminar
Tuesday 15th March, 2016
AstraZeneca PLC at Barclays Global Healthcare Conference
Tuesday 15th March, 2016
AstraZeneca PLC at Exane Bnp Healthcare Conference
Monday 7th March, 2016
AstraZeneca PLC at Cowen Health Care Conference
Wednesday 2nd March, 2016
AstraZeneca PLC at Credit Suisse One-on-One Healthcare Conference
Monday 29th February, 2016
AstraZeneca PLC at Daiwa Investment Conference
Thursday 18th February, 2016
Dividend For AZN.L
Wednesday 17th February, 2016
Dividend For AZN
Wednesday 17th February, 2016
Dividend For AZN.BA
Monday 8th February, 2016
AstraZeneca PLC Investor Roadshow-Europe, North America
Wednesday 10th February, 2016
AstraZeneca PLC at Leerink Partners Global Healthcare Conference
Thursday 4th February, 2016
Full Year 2015 AstraZeneca PLC Earnings Call
Thursday 4th February, 2016
Full Year 2015 AstraZeneca PLC Earnings Release
Wednesday 13th January, 2016
AstraZeneca PLC at JPMorgan Healthcare Conference
Thursday 17th December, 2015
AstraZeneca PLC Conference Call to Discuss Majority Stake Investment in Acerta Pharma

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Should you buy AZN

Access AZN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis